Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
Gene Transfer Technologies Market to Hit US$5.93 Billion by 2029 with 9.7% CAGR | MarketsandMarkets
The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 ...
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job
WASHINGTON — Robert F. Kennedy Jr. is distancing himself from his anti-vaccine work as he seeks to become the leader of the ...
Why Is Merck & Co., Inc. (MRK) Among the Best Large-Cap Value Stocks to Buy in 2025?
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...
Is Merck & Co., Inc. (MRK) the Best Stock to Invest In For Steady Dividends?
We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...
Veterinary Vaccines Market to Hit US$13.33 Billion by 2029 with 6.1% CAGR | MarketsandMarkets
The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion ...